CUSTIRSEN IN COMBINATION WITH DOCETAXEL AND PREDNISONE FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (SYNERGY TRIAL): A PHASE 3, MULTICENTRE, OPEN-LABEL, RANDOMISED TRIAL ArticleChi K.N., Gleave M., Higano C.S., Blumenstein B., Ferrero J.M., Reeves J., Feyerabend S., Stenzl A., Gravis G., Merseburger A.S., Bergman A.M., Mukherjee S.D., Zalewski P., Saad F., Jacobs C., De Bono J.S.The Lancet Oncology. Том 18. 2017. С. 473-485
AFLIBERCEPT VERSUS PLACEBO IN COMBINATION WITH DOCETAXEL AND PREDNISONE FOR TREATMENT OF MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (VENICE): A PHASE 3, DOUBLE-BLIND RANDOMISED TRIAL ArticleTannock I.F., Fizazi K., Ivanov S., Thellenberg Karlsson, Flechon A., Skoneczna I., Orlandi F., Gravis G., Matveev V., Bavbek S., Gil T., Viana L., Aren O., Karyakin O., Elliott T., Birtle A., Magherini E., Hatteville L., Petrylak D., Tombal B. ...The Lancet Oncology. Том V14. 2013. С. 760-768
